Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Everest Medicines' Partner Venatorx Receives FDA Acceptance and Priority Review of New Drug Application for Cefepime-Taniborbactam to Treat Complicated Urinary Tract Infections (cUTI) 2023-08-15 20:19
Everest Medicines to Announce First Half 2023 Financial Results on August 24, 2023 2023-08-09 08:06
Everest Medicines Announces Completion of Patient Enrollment in Nefecon® China Open Label Extension Study 2023-08-01 08:47
Everest Medicines Announces Commercial Launch and First Prescription for XERAVA® in China 2023-07-27 08:10
Everest Medicines' Partner Calliditas Therapeutics Makes Data Presentations on Nefecon at European Renal Association - European Dialysis and Transplant Association Congress (ERA-EDTA ) 2023-06-21 08:15
Everest Medicines Appoints Dr. Mike Berry as Chief Technology Officer 2023-06-16 07:45
Everest Medicines Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Etrasimod in Asia 2023-05-17 07:48
Nefecon Included in the Reimbursement Drug List of "Beijing Puhui Health Insurance Program" as a First-in-Disease Therapy for IgA Nephropathy 2023-05-12 07:40
Everest Medicines Launches Nefecon in China's Hainan Boao Pilot Zone as a First-in-Disease Therapy for IgA Nephropathy 2023-04-24 07:44
Everest Medicines Announces Strategic Partnership with Shanghai Pharma Subsidiary to Accelerate the Commercialization of XERAVA in Mainland China 2023-04-19 08:12
Everest Medicines Announces New Drug Application Acceptance by Singapore HSA for Nefecon for the Treatment of Primary IgA Nephropathy 2023-04-06 07:30
Everest Medicines Announces Financial Results for Full Year Ended December 31, 2022 2023-03-31 07:30
Everest Medicines Receives Full Upfront Payment from Gilead for Trodelvy-Related Transaction, Boosting Pro Forma Cash Reserves 2023-03-27 08:15
Everest Medicines Announces Signing of an MOU for Strategic Cooperation with Guangdong Academy of Medical Sciences in Renal Diseases 2023-03-23 17:52
Everest Medicines to Announce Full-Year 2022 Financial Results on March 31, 2023 2023-03-15 20:45
Everest Medicines Announces Partner Calliditas Therapeutics Reports Positive Topline Results from Phase 3 NefIgArd Trial Evaluating Nefecon in IgA Nephropathy 2023-03-14 07:30
Everest Medicines Announces Silicon Valley Bank Developments Have Minimal Impact on Company 2023-03-13 07:51
Everest Medicines Hosts Ceremony to Celebrate Commencement of Operations at its State-of-the-Art mRNA Vaccine Manufacturing Facility 2023-02-28 07:30
Everest Medicines Announces South Korea Grants Fast Track Review Designation to Nefecon for the Treatment of Primary IgA Nephropathy 2023-02-10 07:30
Everest Medicines Announces Top-line Data from Phase I Study of EVER206 on Healthy Subjects in China 2023-01-18 07:30
1 2 3 4 5 7